• Founded: 2018
  • Location: Cambridge, MA
  • Employee range: 11 - 50
  • Clinical stage: RD
  • Therapy area: Immuno-oncology
  • Drug types: ONC
  • Lead product: Flowfect platform
  • Product link:
  • Funding: $30M A Sep 2021; $3.6M seed May 2019

job board

Short description:

Gene-modified Cell Therapies

Drug notes:

Cell engineering process for cell therapy applications

Long description:

Kytopen is advancing cell therapies by developing novel transfection technologies. Cell therapies involve the delivery of a payload to a desired cell, but some cells are challenging to target. Kytopen is using their platform, Flowfect, to optimize non-viral delivery molecules that get into hard-to-transfect cells. Flowfect uses fluid flow with electric fields to deliver, with high efficiency, payloads of mRNA, DNA and CRISPR Cas9 RNP to primary cells. Kytopen’s approach circumvents the harmful effects of traditional transfection approaches such as static electroporation allowing cells to be engineered with minimal impact to their health and function. Currently, Flowfect can process billions of cells in minutes making it amenable to autologous and allogeneic cell therapy applications.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy